Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia and a condition associated with extreme morbidity, mortality, and cost. The currently available AADs have various safety risks and efficacy limitations. As a result, physicians report high unmet need for safe and efficacious therapies to improve quality of life for AF patients. Based on quantified physician perception of current therapies, we discuss the attractiveness of drug attributes and the implications for AF drug development. It is important to understand the influence of key efficacy, safety/tolerability, and nonclinical attributes on physician prescribing behavior to achieve commercial success with AADs within this indication. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for AF.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 30 European cardiologists fielded in February 2018.
Key companies: Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer.
Key drugs: Amiodarone, dronedarone, flecainide, propafenone.